Navigation Links
Efavirenz-based initial therapies associated with better outcomes in HIV-infected adults
Date:10/14/2008

A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine. Nevirapine is the most frequently prescribed drug for patients undergoing highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS in sub-Saharan Africa, where the study was conducted. The study is published in the October 18, 2008 issue of the journal AIDS.

"Our findings add to existing limited evidence that efavirenz-based therapies produce a more favorable virological and clinical outcome than nevirapine," says Jean Nachega, MD, PhD, MPH, lead author of the study and associate scientist with the Bloomberg School's Department of International Health. "Patients started on nevirapine had an increased risk of virologic failure and death, were significantly less likely than those started on efavirenz to achieve high treatment adherence."

Nachega, in collaboration with Gary Maartens, MD, FCP, professor of Medicine at University of Cape Town, and several other colleagues from the University of Cape Town in South Africa, examined the records of 2,817 HIV- infected adults currently enrolled in Aid for AIDS, a private-sector employer-subsidized disease management program in Africa. Participants were HAART nave adults who began nevirapine-based or efvirenz-based therapies between January 1998 and September 2004. Researchers determined how often patients requested reimbursement for their purchases of nevirapine- or efavirenz-based HAART to estimate adherence to their treatment regimens. They also evaluated patients CD4 counts, viral load changes and mortality, which are measurements that indicate how well a treatment is working. Program participants were in nine countries in Africa with the majority in South Africa.

Current World
'/>"/>

Contact: Tim Parsons
tmparson@jhsph.edu
410-955-7619
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Page: 1 2

Related biology news :

1. Catcher Holdings Inc. Lands Contract for Initial Deployments at Nine Homeland Security and State Government Agencies
2. Carnegie Mellon scientists investigate initial molecular mechanism that triggers neuronal firing
3. Landmark study unlocks stem cell, DNA secrets to speed therapies
4. Argyrin: Natural substance raises hope for new cancer therapies
5. Newly identified role for power plants in human cells could lead to targeted therapies
6. 2 new therapies show promise for cancer patients
7. Challenges and promise of cell-based therapies
8. The construction of heart modelling leads path to new therapies
9. NCI renewal grant to develop new cancer therapies
10. Linchpin gene may be useful target for new breast cancer therapies
11. Low sperm count may be associated with prenatal testosterone excess
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 , Europe,s ... The European Patent Office to present a video retrospective of ... to be featured: Christofer Toumazou and Sophie Wilson ... and winners of the Award   Starting on 22 ...
(Date:12/22/2014)... SHELTON, Conn. , Dec. 22, 2014  NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile commerce ... consultant, Apollo Robbins for the 2015 International CES ... Apollo Robbins will be at the NXT-ID booth ...
(Date:12/19/2014)... 2014  23andMe, Inc., the leading personal genetics company, today announced ... genetic ancestry of individuals from across the United ... than four hundred years ago, the United States ... from different continents. This study illuminates how American history and ...
Breaking Biology News(10 mins):Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 423andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4
... a child is born with a heart defect such as a ... to an inability to quickly and safely secure devices inside the ... stress on fragile heart tissue, and currently available clinical adhesives are ... the presence of blood or under dynamic conditions, such as in ...
... (Maximizing Access to Research Careers) Program has announced ... Society (APS) Professional Skills Training Course in Orlando, ... meant to promote the entry of underrepresented minority ... the basic science community and to encourage the ...
... in German . ... Institute of Immunobiology and Epigenetics, has sequenced and analyzed the genome ... human and other vertebrate genomes has revealed why the skeleton of ... the human skeleton and that the immune system of the shark ...
Cached Biology News:Bio-inspired glue keeps hearts securely sealed 2Bio-inspired glue keeps hearts securely sealed 3First shark genome decoded 2
(Date:12/25/2014)... December 25, 2014 The report “Service ... Product Type & Provider Type - Global Advancements, Worldwide ... with an in-depth analysis and forecasting of revenues. ... through 221 pages and in-depth TOC on “Service Quality ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, ... company advancing patient care in critical areas, announced the closing ... stock, and warrants to purchase up to an aggregate 3,500,000 ... per share and $.01 per warrant.  The warrants have a ...
(Date:12/24/2014)... Dec. 24, 2014   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and cryopreservation ... for cells and tissues  ("BioLife" or the "Company"), today announced ... on May 4, 2015 (the "Annual Meeting"). Because ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed across ... in the process of being consolidated in a Kansas federal ... Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 in ... Management of the Syngenta GMO corn multidistrict litigation (MDL) has ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2
... Pharmaceuticals Inc. (Nasdaq: VNDA ), a biopharmaceutical ... product candidates for central nervous system disorders, today announced ... December 31, 2008. Vanda reported a net loss ... compared to $10.9 million for the third quarter of ...
... Development Conference features presentations from industry and academic speakers who ... and chemical industries. Topics include Chemical and Process R&D, ... by Design (QbD). , ... Columbia, ...
... New Mexico, February 10, 2009A team of Los Alamos ... multiplicationwhen a photon creates multiple electronsis a real phenomenon ... born of extraneous effects that mimic carrier multiplication. The ... of Chemical Research , shows the possibility of solar ...
Cached Biology Technology:Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 2Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 3Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 4Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 5Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 6Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 7Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 8Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 9Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results 1016th International Process Development Conference to be Held June 14-17, 2009 in Arosa, Switzerland 2Research highlights potential for improved solar cells 2Research highlights potential for improved solar cells 3
sodium channel, nonvoltage-gated 1 alpha,...
MOUSE ANTI HUMAN B-CELLS (FMC7):FITC Immunogen: HRIK cells - Human B-Lymphoblastoid line...
RABBIT ANTI PARATHION...
Similar to proteasome (prosome, macropain) 26S subunit, ATPase, 1 Antigen: Recombinant Protein...
Biology Products: